October 2021

The ability to inhibit mitophagy converts fluorizoline into a promising antitumor agent

Fluorizoline was known for its pro-apoptotic action on various tumor cells. Now, a study by IDIBELL and the University of Barcelona shows that apart from promoting cell death, this compound inhibits the degradation of mitochondria.

The ability to inhibit mitophagy converts fluorizoline into a promising antitumor agent Read More »

Recognition of Dr. Mònica Povedano and the Functional Unit for Motor Neuron Disease work

Dr. Mònica Povedano, principal investigator at IDIBELL and head of the Functional Unit for Motor Neuron Disease at the Bellvitge University Hospital, has been awarded the 2020 Neuromuscular Disease Prize (scientific modality), granted by the Spanish Society of Neurology (SEN).

Recognition of Dr. Mònica Povedano and the Functional Unit for Motor Neuron Disease work Read More »

Cervical cytologies are not sensitive enough to detect endometrial cancer

The screening programs of cervical cancers diagnosticated by cervical cytologies have reduced the incidence and mortality of this cancer. However, a retrospective study of IDIBELL and ICO that included 371 women treated at the Hospital de Bellvitge has shown that these tests are not effective for endometrial cancer diagnosis.

Cervical cytologies are not sensitive enough to detect endometrial cancer Read More »

IDIBELL participates in a study aimed to reduce the likelihood of liver failure in older transplant donors

MCJ protein silencing emerges as a new therapy to prevent liver failure after ischaemia-reperfusion in models of metabolic syndrome and ageing.

IDIBELL participates in a study aimed to reduce the likelihood of liver failure in older transplant donors Read More »

Scroll to Top